Trial · NCT00306150
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
NCT00306150, Phase 3, Terminated, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy. Trials, record NCT00306150. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00306150
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
- NCT number
- NCT00306150
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 57 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Blood Loss, Surgical, Postoperative Hemorrhage
- Interventions
- Trasylol (Aprotinin, BAYA0128), Placebo
- First posted
- 2006-03-23
- Last updated
- 2014-12-17
- Other registries' IDs
- eudract:2005-004055-35
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary criterion for efficacy is the percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge) | Anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge) | |
| Secondary | The number of units of blood or packed red cells transfused. There will be an analysis for the combination of autologous and allogenic transfusion and for allogenic alone | Intra- and postoperative | |
| Secondary | The number of units of blood or packed red cells transfused per patient requiring transfusion | Intra- and postoperative | |
| Secondary | The intraoperative blood loss determined as follow: a) by surgeon estimate b) summing weight of the blood in gauze and other materials and the suction drainage volume | Intraoperative | |
| Secondary | The drainage volume (in milliliters) from the operative site | In the first 8 hours post-operatively, and daily total drainage until removal of drains or until discharge, whichever comes first | |
| Secondary | Transfusion of platelets, colloids, plasma and number of patients requiring these products | Intra- and postoperative | |
| Secondary | The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration | Obtained in the morning of postoperative Day 3, or, if transfused earlier, prior to transfusion | |
| Secondary | Surgeon s assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures | Intraoperative | |
| Secondary | Changes in blood markers related to inflammation and blood coagulation; baseline until Discharge or day 7 | Several measurements from baseline up to 6 weeks | |
| Secondary | Time to discontinuing of mechanical ventilation | Not specifed |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00306150
GET https://conductscience.org/api/trials/v1/NCT00306150/registered